Accelerated Development of VAcciNe outcome research Collaboration in Europe
The ADVANCE vision is focused on timely and best evidence on vaccine effects. The mission is to establish a Blueprint for a validated and tested best practice framework that could rapidly provide robust data on vaccine benefits and risks to support accelerated decision making.
This is a EU-funded collaboration between researchers, public health and industry with the aim to build an integrated and sustainable framework for continuous vaccine effect monitoring in order to evaluate the benefit-risk of vaccines and to maintain public trust in Europe.
In Europe there is a need to achieve continuous benefit risk assessment throughout the life cycle of vaccines. This would encompass: Rapid verification of safety issues with a prior hypothesis utilizing all available information sources (e.g. clinical trial data, spontaneous reporting data, data from electronic health care record; Thorough signal substantiation (hypothesis testing studies); Effectiveness of vaccine utilizing available data sources (e.g. clinical trial data, pathogen/vaccine targeted disease surveillance data and data from electronic health care records); Population impact assessment of intended vaccine effect utilizing available data sources (e.g. clinical trial data, pathogen/vaccine targeted disease surveillance data, data from electronic health care records); Integrated vaccine benefit-risk assessment with the option for cyclical updates during the vaccine life cycle.
This collaboration commenced during the latter half of 2013 and is funded for 5 years.
Project period: 2013-2018
Main financing: EU